A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.

Details

Language :

English

ISSN :

15560864

Volume :

15

Issue :

1

Database :

Complementary Index

Journal :

Journal of Thoracic Oncology

Publication Type :

Academic Journal

Accession number :

145439781

Full Text :

https://doi.org/10.1016/j.jtho.2019.10.003